Evolva’s Veri-te resveratrol fights cognitive decline in post-menopausal women
06 Apr 2020 --- Daily supplementation with Evolva’s Veri-te resveratrol ingredient can improve cognitive performance and reduce the decline in cerebrovascular responsiveness (CVR) of postmenopausal women. This is according to the first findings of the Resveratrol Supporting Healthy Aging in Women (RESHAW) clinical study, which makes for the largest, longest-running study of its kind with resveratrol. The newly Nutrients-published study highlights that regular consumption of resveratrol can support the cause against cognitive decline, considering that independent of life expectancy, dementia mortality rates in global women in 2016 were almost twice that of men.
“The RESHAW clinical study provides evidence that supplementation with Veri-te resveratrol should be a key strategy for the design and delivery of effective supplements as women age. This is to improve overall well-being post-menopause,” says Clare Panchoo, Vice President of Health Ingredients, Evolva.
The research team randomized 129 postmenopausal women aged 45 to 85 years to take either a placebo or 75 mg of trans-resveratrol twice daily for 12 months. The researchers assessed the effects on cognition, cerebral blood flow, CVR as well as cardiometabolic markers, including blood pressure, diabetes markers and fasting lipids.
Performance changes in cognitive domains following placebo and resveratrol treatments.The findings of the new study “confirm the previous observations in both men and women that a regular low dose of resveratrol can sustain cerebrovascular function,” says co-author Professor Peter Howe from the University of Newcastle, Australia. This was most evident in the elderly female test subjects, he highlights. Furthermore, the study found that cognitive benefits can be sustained with ongoing supplementation for at least 12 months.
“The low dose of resveratrol was well tolerated without apparent side effects. Our findings support the adoption of resveratrol as a low-cost, effective intervention to help counteract the age and menopause-related accelerated cognitive decline in aging populations,” the study reads.
Having demonstrated an association of resveratrol-induced changes in fasting glucose with improvements in endothelial vasodilator function, the researchers note this warrants further investigation. Further aiming to establish resveratrol as a viable intervention for healthy aging, the researchers conclude that subsequent publications from this study will report the effects of resveratrol on bone health, physical function and quality of life measures.
Delivery formats of Veri-te
In addition to more clinical studies, Evolva is looking to provide the customer with ingredient solutions for a variety of product formulations. The company is currently looking at new delivery forms to allow Veri-te resveratrol to be formulated into functional beverages and ready-mix powders.
“We understand that consumers are looking for new and easier ways to consume supplements besides always taking traditional pills and capsules. That is the reason for introducing Veri-Sperse CWD 90 last year and Veri-te Aqua this upcoming summer,” David Tetzlaf, Director of Marketing at Evolva, tells NutritionInsight.
Other than cognitive decline, resveratrol has shown antidepressant and anti-stress effects by blocking the expression of an enzyme related to the control of stress in the brain. Commonly known as a central compound found in red wine, resveratrol has also demonstrated its range of health benefits in the alcoholic beverage.
By Anni Schleicher
